Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
PEPTAVO
The Stack Source LLC1908 E 11th Street Austin, TX 78702support@peptavo.com(512) 827-8158DBA: Peptavo
Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
Off-label peptides are FDA-approved peptide drugs prescribed outside their labeling, and a licensed prescriber may do that when it is medically appropriate. The term only covers approved drugs. Compounded and research use only peptides have no label, so different rules apply to them. Here is where the line sits.
Off-label peptides are FDA-approved peptide drugs prescribed for a use, dose, patient group, or route that their labeling does not include, and a licensed prescriber may lawfully do that when they judge it medically appropriate for the patient. The term applies only to approved drugs, so a compounded or research use only peptide cannot be prescribed off label: it has no FDA label to step outside, and its legality turns on the compounding rules instead.
Most confusion about peptide prescribing starts with treating those three kinds of product as one. This guide sets out what off-label prescribing allows, the limits that still apply to it, how it differs from compounding, and what to document before writing the prescription.
Status as of October 27, 2026. This guide covers federal law and general state practice. Scope of practice, telehealth, and board rules vary by state; see our guide to who can prescribe peptides for license-by-license detail.
FDA approves a drug for the uses, doses, and populations its sponsor studied, and the approved labeling, the package insert, describes exactly those. FDA's own guidance on unapproved use of approved drugs states that once a drug is approved, "healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient."
That works because FDA regulates how drugs are marketed, and states regulate how medicine is practiced. A prescription is off label when any of these differ from the labeling:
| Departure | Example with an approved peptide drug |
|---|---|
| Indication | Prescribing a drug approved for one condition to treat a different one |
| Population | Prescribing to men a drug approved only for premenopausal women |
| Dose or schedule | Using a dose, titration, or frequency the label does not describe |
| Route | Giving the drug by a route other than the approved one |
| Duration | Continuing treatment past the period studied in the label |
Off-label use is common across medicine and is not a mark against the prescriber. It does move the evidence burden onto the prescriber, because the label no longer stands behind the choice.
Before asking whether an off-label use is allowed, establish what the product is.
| Product | Has an FDA label? | Can it be prescribed off label? | What governs it |
|---|---|---|---|
| FDA-approved peptide drug | Yes | Yes, within state scope and the standard of care | The approved labeling, state practice law, payer rules |
| Compounded peptide from a 503A pharmacy or 503B outsourcing facility | No | The term does not apply | Section 503A or 503B of the FD&C Act, the bulk substance rules, state pharmacy law |
| Research use only peptide | No | No, and it has no lawful prescribing pathway | Not a lawful prescription drug for humans |
A compounded drug is an unapproved drug that federal law permits under conditions. Under 21 U.S.C. 353a, a drug compounded by a licensed pharmacist for an identified patient on a valid prescription is exempt from the approval requirement, the requirement for adequate directions for use, and federal manufacturing rules, provided its bulk substance qualifies. Whether a given peptide qualifies is a compounding question, and the answer is moving: in July 2026 FDA's Pharmacy Compounding Advisory Committee recommended six peptides for the 503A bulks list, and those votes take effect only if FDA acts on them. Our map of the FDA compounding categories tracks the current status. The differences between pharmacy types are in our guide to 503A vs. 503B pharmacies.
Research use only products are neither approved nor lawfully compounded, so off-label reasoning cannot rescue them. Our guide to research use only peptides covers why.
Several approved peptide drugs carry narrow labels, which is why off-label requests for them are frequent.
Tesamorelin is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its labeling states it is not indicated for weight loss. Prescribing it for body composition in patients without HIV is off label.
Bremelanotide is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Its labeling states it is not indicated for postmenopausal women or for men, so prescribing it to either is off label.
GLP-1 receptor agonists are approved for type 2 diabetes, chronic weight management, and specific cardiovascular and kidney indications, each at labeled doses. Microdosing schedules and uses outside those indications are off label.
In each case the drug itself is lawful and FDA-approved, so the open questions are whether the evidence supports the use for this patient and whether the prescriber has documented that judgment.
Off-label authority is broad. These are the places it stops.
Growth hormone. Human growth hormone is the one peptide hormone where off-label distribution is a federal crime. Under 21 U.S.C. 333(e), distributing or possessing with intent to distribute it "for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary" is punishable by up to five years in prison. Anti-aging and athletic performance uses fall outside that authorization. Growth hormone secretagogues are separate drugs and sit outside this statute.
Copies of approved drugs. A 503A pharmacy may not regularly compound what is essentially a copy of a commercially available drug, under 21 U.S.C. 353a(b)(1)(D). FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025, and the temporary allowance for compounded copies ended in 2025. On April 30, 2026, FDA also proposed keeping semaglutide, tirzepatide, and liraglutide off the 503B bulks list, which would bar outsourcing facilities from compounding them from bulk substance outside a shortage. The comment period closed in July, and no final decision had been published when this guide was updated. A compounded version of an approved peptide now needs a documented clinical difference for the specific patient, such as a dose the commercial product cannot deliver or an excipient the patient cannot tolerate, recorded on the prescription.
Scope of practice. A nurse practitioner or physician assistant prescribes off label only as far as state law and the practice agreement allow. Some agreements say nothing about off-label use, which is a gap to close in writing. Our guides for nurse practitioners and physician assistants cover the agreements.
The standard of care. The American Medical Association's policy H-120.988 supports a physician's lawful use of an approved drug for an unlabeled indication when sound scientific evidence or sound medical opinion supports it. Medical boards and malpractice courts judge an off-label prescription against what a reasonable prescriber would do with the same evidence. Thin evidence does not make the prescription unlawful, but it raises the bar for the record behind it.
Promotion. Federal limits on promoting off-label uses bind manufacturers and distributors. A clinic that advertises a peptide for an off-label use still answers to the Federal Trade Commission's requirement that health claims be substantiated, and to its state board's advertising rules. Claims a clinic cannot support with evidence are a common trigger for complaints.
Coverage is narrower than prescribing authority. Medicare Part D pays for a drug only for a medically accepted indication, which federal law defines as an FDA-approved use or one supported by a citation in a recognized compendium such as AHFS Drug Information or DRUGDEX (42 U.S.C. 1396r-8(k)(6), applied to Part D by 42 U.S.C. 1395w-102(e)). Commercial plans set their own rules and usually require prior authorization for off-label use. Compounded peptides are rarely covered at all, which is why most peptide therapy is cash pay. Tell patients before the first fill.
Federal law does not require telling a patient that a use is off label. State informed consent law does require disclosing material risks, benefits, and alternatives, and when the evidence for a use is limited, that limitation is material. The chart should show the reasoning a board reviewer would look for.
| Record | What it should show |
|---|---|
| Product and status | The drug, that it is FDA-approved, and that this use is off label |
| Indication | The diagnosis or goal, and why approved options were not used or did not work |
| Evidence | The studies, guidelines, or compendium listings relied on |
| Consent | That the patient was told the use is off label, what the evidence shows, the risks, and the cost |
| Dose and monitoring | The dose and why, baseline labs, follow-up schedule, and stop criteria |
| Source | The dispensing pharmacy, and for a compounded version, the clinical difference that justifies it |
Our peptide therapy consent kit includes an off-label and compounded product disclosure you can adapt to your practice.
Prescribing off label well depends on knowing the labeled indications, the evidence for each off-label use, the compounding rules, and how to document all of it. Our peptide course for physicians covers each, with protocols, consent templates, and patient cases, and is designated for up to 20 AMA PRA Category 1 Credits™.
Yes, for FDA-approved peptide drugs. A licensed prescriber may prescribe an approved drug for an unapproved use when they judge it medically appropriate, within state scope of practice and the standard of care. The main federal exception is growth hormone, where off-label distribution is a crime.
The term does not apply to them. A compounded peptide has no FDA label, so there is no approved use to depart from. It is lawful when a licensed pharmacy compounds it from a qualifying bulk substance on a valid prescription for an identified patient.
No. Research use only peptides are not approved drugs and are not lawfully compounded, so they have no prescribing pathway at all. Off-label reasoning does not apply to them.
Federal law does not require it, but state informed consent law requires disclosing material risks, benefits, and alternatives. With limited evidence, the off-label status and the strength of the evidence are both material, so disclose them and document that you did.
Yes, where state law gives them prescriptive authority and their practice agreement or formulary allows it. Where the agreement is silent on off-label use, amend it before prescribing.
Sometimes. Medicare Part D covers off-label uses only when a recognized compendium supports them, and commercial plans usually require prior authorization. Compounded peptides are rarely covered.